141 related articles for article (PubMed ID: 24566014)
1. Multivariable model consisting of clinical and biological markers for time to first treatment in CLL patients: Preliminary results from single centre experience.
Trajkova S; Cevreska L; Pivkova-Veljanovska A; Ivanovski M; Dukovski D; Popova-Simjanovska M; Cadievski L; Eftimov A; Dimovski A; Panovska-Stavridis I
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):39-47. PubMed ID: 24566014
[TBL] [Abstract][Full Text] [Related]
2. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia].
Motyčková M; Smolej L; Andrýs C; Rezáčová V; Reháček V; Simkovič M; Belada D; Zák P
Vnitr Lek; 2013 Sep; 59(9):782-93. PubMed ID: 24073950
[TBL] [Abstract][Full Text] [Related]
4. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
5. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
6. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Wierda WG; O'Brien S; Wang X; Faderl S; Ferrajoli A; Do KA; Garcia-Manero G; Cortes J; Thomas D; Koller CA; Burger JA; Lerner S; Schlette E; Abruzzo L; Kantarjian HM; Keating MJ
J Clin Oncol; 2011 Nov; 29(31):4088-95. PubMed ID: 21969505
[TBL] [Abstract][Full Text] [Related]
7. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
Molica S; Digiesi G; Mirabelli R; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Morabito F; Neri A; Baldini L; Ferrarini M
Eur J Haematol; 2009 Sep; 83(3):208-14. PubMed ID: 19459926
[TBL] [Abstract][Full Text] [Related]
8. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.
Condoluci A; Terzi di Bergamo L; Langerbeins P; Hoechstetter MA; Herling CD; De Paoli L; Delgado J; Rabe KG; Gentile M; Doubek M; Mauro FR; Chiodin G; Mattsson M; Bahlo J; Cutrona G; Kotaskova J; Deambrogi C; Smedby KE; Spina V; Bruscaggin A; Wu W; Moia R; Bianchi E; Gerber B; Zucca E; Gillessen S; Ghielmini M; Cavalli F; Stussi G; Hess MA; Baumann TS; Neri A; Ferrarini M; Rosenquist R; Forconi F; Foà R; Pospisilova S; Morabito F; Stilgenbauer S; Döhner H; Parikh SA; Wierda WG; Montserrat E; Gaidano G; Hallek M; Rossi D
Blood; 2020 May; 135(21):1859-1869. PubMed ID: 32267500
[TBL] [Abstract][Full Text] [Related]
9. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
[TBL] [Abstract][Full Text] [Related]
10.
Habashy DM; Eissa DS; Aboelez MM
Turk J Haematol; 2018 Aug; 35(3):168-174. PubMed ID: 28884705
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.
Sulda ML; Kuss BJ; Hall RK; Bailey S; Macardle PJ
Intern Med J; 2012 Feb; 42(2):137-46. PubMed ID: 20561095
[TBL] [Abstract][Full Text] [Related]
12. Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features.
Vrbacky F; Smolej L; Vroblova V; Pekova S; Hrudkova M; Cervinka M; Pecka M; Krejsek J; Maly J
Hematology; 2010 Aug; 15(4):210-4. PubMed ID: 20670479
[TBL] [Abstract][Full Text] [Related]
13. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
[TBL] [Abstract][Full Text] [Related]
14. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
[TBL] [Abstract][Full Text] [Related]
15. Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.
Visentin A; Facco M; Frezzato F; Castelli M; Trimarco V; Martini V; Gattazzo C; Severin F; Chiodin G; Martines A; Bonaldi L; Gianesello I; Pagnin E; Boscaro E; Piazza F; Zambello R; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):612-20.e1-5. PubMed ID: 26233718
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
[TBL] [Abstract][Full Text] [Related]
17. Serum carbohydrate antigen 125 is not an independent prognostic factor in patients with chronic lymphocytic leukemia.
Zou ZJ; Fan L; Wang L; Zhang R; Zhang LN; Yang S; Li JY; Xu W
Cancer Biomark; 2012; 12(4):169-76. PubMed ID: 23568007
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of immunoglobulin variable heavy chain gene mutation status: long term follow-up in a series of chronic lymphocytic leukemia patients.
Panovska-Stavridis I; Cevreska L; Stojanovic A; Efremov D
Prilozi; 2006 Dec; 27(2):127-37. PubMed ID: 17211297
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia].
Zhu HY; Wang L; Qiao J; Zou YX; Xia Y; Wu W; Cao L; Liang JH; Fan L; Xu W; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):392-397. PubMed ID: 29779348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
